RVL Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
RVL Pharmaceuticals has been growing earnings at an average annual rate of 16.3%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been declining at an average rate of 49.3% per year.
Key information
16.3%
Earnings growth rate
24.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | -49.3% |
| Return on equity | -418.1% |
| Net Margin | -184.9% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How RVL Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 37 | -68 | 67 | 3 |
| 31 Mar 23 | 37 | -56 | 71 | 4 |
| 31 Dec 22 | 50 | -52 | 79 | 4 |
| 30 Sep 22 | 43 | -53 | 85 | 4 |
| 30 Jun 22 | 35 | -66 | 93 | 5 |
| 31 Mar 22 | 38 | -76 | 91 | 4 |
| 31 Dec 21 | 18 | -83 | 84 | 6 |
| 30 Sep 21 | 16 | -115 | 81 | 9 |
| 30 Jun 21 | 40 | -86 | 74 | 9 |
| 31 Mar 21 | 28 | -82 | 72 | 11 |
| 31 Dec 20 | 28 | -89 | 73 | 13 |
| 30 Sep 20 | 87 | -64 | 75 | 18 |
| 30 Jun 20 | 126 | -178 | 78 | 24 |
| 31 Mar 20 | 183 | -285 | 90 | 27 |
| 31 Dec 19 | 240 | -271 | 93 | 32 |
| 30 Sep 19 | 246 | -351 | 95 | 38 |
| 30 Jun 19 | 247 | -243 | 88 | 40 |
| 31 Mar 19 | 261 | -112 | 79 | 43 |
| 31 Dec 18 | 264 | -110 | 74 | 43 |
| 30 Sep 18 | 274 | -1 | 67 | 53 |
| 30 Jun 18 | 262 | -10 | 63 | 50 |
| 31 Mar 18 | 248 | -31 | 60 | 47 |
| 31 Dec 17 | 246 | -41 | 57 | 42 |
| 31 Dec 16 | 218 | -42 | 63 | 29 |
Quality Earnings: O1P is currently unprofitable.
Growing Profit Margin: O1P is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: O1P is unprofitable, but has reduced losses over the past 5 years at a rate of 16.3% per year.
Accelerating Growth: Unable to compare O1P's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: O1P is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (3.7%).
Return on Equity
High ROE: O1P has a negative Return on Equity (-418.14%), as it is currently unprofitable.